MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.

Gan, Tian; Wang, Yan; Xie, Manyi; Wang, Qiang; Zhao, Saisai; Wang, Peng; Shi, Qinyu; Qian, Xuanchen; Miao, Faan; Shen, Zhigang; Nie, Er

Gan, Tian; Wang, Yan; Xie, Manyi; Wang, Qiang; Zhao, Saisai; Wang, Peng; Shi, Qinyu; Qian, Xuanchen; Miao, Faan; Shen, Zhigang; Nie, Er.

Afiliação

Gan T; Department of Endocrinology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Wang Y; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Xie M; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Wang Q; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Zhao S; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Wang P; Department of Neurosurgery, Rizhao Central Hospital, Rizhao, Shandong Province, P.R. China.
Shi Q; Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China.
Qian X; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Miao F; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Shen Z; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.
Nie E; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, P.R. China.

Cancer Res ; 82(22): 4234-4246, 2022 11 15.

Article em En | MEDLINE | ID: mdl-36112059

Assuntos

Antineoplásicos Alquilantes; Neoplasias Encefálicas; Reparo de Erro de Pareamento de DNA; Resistencia a Medicamentos Antineoplásicos; Glioblastoma; Proteína 2 Homóloga a MutS; Temozolomida; Humanos; Antineoplásicos Alquilantes/farmacologia; Antineoplásicos Alquilantes/uso terapêutico; Neoplasias Encefálicas/tratamento farmacológico; Neoplasias Encefálicas/genética; Neoplasias Encefálicas/patologia; Linhagem Celular Tumoral; Dacarbazina/farmacologia; Dacarbazina/uso terapêutico; Metilases de Modificação do DNA/genética; Metilases de Modificação do DNA/metabolismo; Enzimas Reparadoras do DNA/genética; Enzimas Reparadoras do DNA/metabolismo; Resistencia a Medicamentos Antineoplásicos/genética; Glioblastoma/tratamento farmacológico; Glioblastoma/genética; Glioblastoma/metabolismo; Proteína 2 Homóloga a MutS/genética; Proteína 2 Homóloga a MutS/metabolismo; Recidiva Local de Neoplasia/tratamento farmacológico; RNA Mensageiro; Temozolomida/farmacologia; Temozolomida/uso terapêutico; Proteínas Supressoras de Tumor/genética; Proteínas Supressoras de Tumor/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Antineoplásicos Alquilantes / Proteína 2 Homóloga a MutS / Reparo de Erro de Pareamento de DNA / Temozolomida Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google